ALL-052: New Therapeutics in Cancer Treatment: Analysis of Socioeconomic and Demographic Characteristics of Use Among Acute Lymphoblastic Leukemia (ALL) Patients in the United States

Abstract

Objective: Evaluate the socioeconomic dynamics associated with new therapeutics use among acute lymphocytic leukemia (ALL) patients in the United States. Design: This retrospective study included the primary and secondary diagnosis of acute lymphocytic leukemia (ALL) in the National Inpatient Sample (NIS) from the Healthcare Cost and Utilization Project (HCUP) between 2016 and 2018. ALL and new treatment therapeutics, diagnoses, and procedure codes were identified using their corresponding International Classification of Disease (ICD-10) codes. ALL ICD-10 codes were acute lymphoblastic leukemia not having achieved remission (C91.00), acute lymphoblastic leukemia in remission (C91.01), acute lymphoblastic leukemia in relapse (C91.02), and new technologies codes for anatomical regions (XW0, XW1, XW2). Patient characteristics and demographics data were analyzed among the population with both indicators. Chi-squared analysis was also conducted to identify relationships between variables. Results: A weighted sample of 158,090 primary and secondary ALL diagnoses were identified. A total of 2,320 (1%) records with ALL diagnoses were treated with new therapeutics. The most common new therapies included administration of blinatumomab antineoplastic immunotherapy (1.9%), cytarabine and daunorubicin liposome (0.3%), and engineered autologous chimeric antigen receptor T-cell immunotherapy (0.2%). The utilization rate of engineered chimeric antigen varied by sex, with 6,250 males and 3,750 females per 10,000 hospitalizations. Use of new therapeutics varied significantly (p Conclusions: Access to new therapeutics varied by race, income, and region. Therefore, providers and researchers must ensure comprehensive inclusion of all patient populations to better understand new drug effectiveness among these populations.